ELIZABETH M. VAN COTT, MD
MASSACHUSETTS GENERAL HOSPITAL
Boston, Massachusetts
Primary Audience: Phlebotomists, Laboratory Technologists, Laboratory Directors
Secondary Audience: Pathologists, Clinical Scientists (Includes all sub-specialty areas), Students, Pathologist Assistants, Residents, and Students
Upon completion of this activity, you will be able to:
· discuss the new anticoagulants and which factor each inhibits to produce anticoagulant effects;
· describe how the laboratory can determine if these anticoagulants are present in a blood specimen;
· describe the hypercoagulation tests that are adversely affected by the new anticoagulants; and
explain how to monitor warfarin while transitioning from argatroban (or dabigatran or bivalirudin) to warfarin.